Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Deals Business Strategies M & A

Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

  • News

Executive Summary

Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.

You may also be interested in...



Coronavirus Update: How Much Should Remdesivir Cost?

US cost watchdog ICER has released its cost models for remdesivir, and says it wants to stimulate debate on how it and other COVID-19 therapies should be priced. Plus news from Amgen and ILC Therapeutics.

Valneva Snares Pfizer For Lyme Disease Vaccine Pact

Days after inking a COVID-19 collaboration with Dynavax, Valneva has linked up with Pfizer to drive its Lyme disease vaccine VLA15 towards Phase III trials.

Coronavirus Update: Remdesivir Fast-Tracked, GSK's Shingrix Hit Hard By Lockdown

Results from the first major trial of remdesivir are positive, but fail to show clear mortality benefit - making its forthcoming approval just the first step towards winning the war on COVID-19.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Pink Sheet

Topics

Related Companies

Tags:
Deals Business Strategies M & A
UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By